BEAU BURTON: Open Payments
NPI 1992117436 · RUSTON, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,264 in 124 payments from 24 companies in 2025. Trend: 2023 $2,144 · 2024 $2,111 · 2025 $2,264
Food & beverage: $2,264
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 21 | $309 |
| Bayer Healthcare Pharmaceuticals Inc. | 10 | $178 |
| Sumitomo Pharma America, Inc. | 8 | $172 |
| Alkermes, Inc. | 11 | $151 |
| AstraZeneca Pharmaceuticals LP | 6 | $135 |
| GlaxoSmithKline, LLC. | 6 | $132 |
| Astellas Pharma US Inc | 7 | $117 |
| Otsuka America Pharmaceutical, Inc. | 5 | $104 |
| Vanda Pharmaceuticals Inc. | 4 | $89 |
| Amgen Inc. | 5 | $89 |
Products named: VRAYLAR, Kerendia, GEMTESA, AIRSUPRA, TRELEGY ELLIPTA, Veozah, ARISTADA, REXULTI.
Industry payments across LA — which companies pay providers there.
